Last €0.0090 EUR
Change Today -0.001 / -10.00%
Volume 0.0
DU8 On Other Exchanges
As of 2:17 AM 09/17/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

60-66 Hanover Street

Fitzroy, VIC 3065


Phone: 61 3 8412 7000

Fax: 61 3 8412 7040

Genetic Technologies Limited, a biotechnology company, provides paternity and related testing services in Australia. Paternity Testing Business The company provides DNA-based individuality testing for the resolution of disputed paternity and the determination of familial relationships for immigration purposes. Other types of tests the company could offer are as follows: Y Chromosome Testing: It determines if two males come from the same paternal line (have a common father or grandfather). Mitochondrial DNA Testing: It determines if two people come from the same maternal line. Sibship Testing: It determines if people are siblings (have the same mother and father). Maternity Testing: It determines the mother of a given child. DNA Typing: It reveals the DNA makeup of an individual. Grandparent Analysis: It determines the grandparents of a given child. Antenatal DNA Testing: It determines the father of an as-yet unborn child. The company issues reports for the Family Court in Australia and provides similar services internationally for the Department of Immigration and Citizenship (DIAC). It is the DNA testing laboratory in Australia recognized by DIAC to provide DNA tests for immigration purposes. Testing Services beyond Paternity Testing Medical Testing: The strategic alliance with Myriad Genetics Inc. delivered to the company rights in Australia and New Zealand to perform DNA testing for susceptibility to a range of cancers. The company joined the worldwide genetic testing network GENDIA as the sole reference laboratory for the network in Australia and New Zealand. GENDIA consists of approximately 50 laboratories worldwide, each contributing expertise in their respective disciplines to create a network capable of providing approximately 2,000 different genetic tests. This has provided the company to offer testing services to its customer base in the Asia-Pacific region, as well as increasing its exposure to other markets. The company has a strategic alliance with Australian biotechnology company, Bionomics Limited, for the commercialization of the diagnostic genetic test for the condition Severe Myoclonic Epilepsy in Infancy. It negotiated an option to investigate the purchase of various assets from Perlegen Sciences, Inc. of Mountain View, California, which included a breast cancer non-familial risk assessment test, BREVAGen. The company’s subsidiary, Phenogen Sciences Inc., markets and distributes the BREVAGen test across the mainland U.S.A. In 2012, the company announced that it had received European CE Mark approval for BREVAGen, which would allow BREVAGen to be sold in the EU and other countries that recognize the CE Mark. Animal Testing: The company owns Genetic Science Services to expand the range of tests the company could offer to include relevant genetic testing in animals, such as progeny testing in horses, dogs, and deer; sexing in birds; and animal disease identification and susceptibility testing for a range of animals, including exotic and zoo animals. The company offers Dog Attack Pack, a forensic tool enabling local government officers to collect samples from dog attacks and BITSA, a breed identification test that uses DNA analysis to provide a history of a dog’s breed. The company also owns Frozen Puppies Dot Com Pty. Ltd., an Australian company specializing in canine reproductive services, following which the company expanded its facilities into territories outside of Australia and developed relationships with breeders and associations in China, Japan, New Zealand, and elsewhere. Plant Testing: The company has a joint venture with the Victorian State Government’s Department of Primary Industry, for the purpose of providing a genotyping service for plant testing - to help plant breeders identify the genes responsible for the detection of commercially relevant traits, such as resistance to disease, accelerated growth, and the improvement of crop yields. Patent Portfolio The company’s major families of patents in the portfolio include Intron Sequence Analysis; Genomic Mapping; Perlegen; BREVAGen; Laboratory Techniques; Ancestral Haplotypes; Athletic Pe

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DU8:GR €0.01 EUR -0.001

DU8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $58.89 USD +0.98
Bristol-Myers Squibb Co $50.88 USD -0.27
Pfizer Inc $30.35 USD +0.30
Sonic Healthcare Ltd A$17.22 AUD +0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation DU8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENETIC TECHNOLOGIES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at